Illinois General Assembly - Full Text of SB1607
Illinois General Assembly

Previous General Assemblies

Full Text of SB1607  100th General Assembly

SB1607sam001 100TH GENERAL ASSEMBLY

Sen. Melinda Bush

Filed: 3/7/2017

 

 


 

 


 
10000SB1607sam001LRB100 11093 RLC 23050 a

1
AMENDMENT TO SENATE BILL 1607

2    AMENDMENT NO. ______. Amend Senate Bill 1607 by replacing
3everything after the enacting clause with the following:
 
4    "Section 5. The Illinois Controlled Substances Act is
5amended by changing Sections 314.5 and 316 as follows:
 
6    (720 ILCS 570/314.5)
7    Sec. 314.5. Medication shopping; pharmacy shopping.
8    (a) It shall be unlawful for any person knowingly or
9intentionally to fraudulently obtain or fraudulently seek to
10obtain any controlled substance or prescription for a
11controlled substance from a prescriber or dispenser while being
12supplied with any controlled substance or prescription for a
13controlled substance by another prescriber or dispenser,
14without disclosing the fact of the existing controlled
15substance or prescription for a controlled substance to the
16prescriber or dispenser from whom the subsequent controlled

 

 

10000SB1607sam001- 2 -LRB100 11093 RLC 23050 a

1substance or prescription for a controlled substance is sought.
2    (a-5) Before issuing a prescription for a Schedule II, III,
3IV, or V controlled substance, a prescriber or his or her
4designee shall access the prescription monitoring program to
5determine compliance with this Section.
6    (b) It shall be unlawful for a person knowingly or
7intentionally to fraudulently obtain or fraudulently seek to
8obtain any controlled substance from a pharmacy while being
9supplied with any controlled substance by another pharmacy,
10without disclosing the fact of the existing controlled
11substance to the pharmacy from which the subsequent controlled
12substance is sought.
13    (c) A person may be in violation of Section 3.23 of the
14Illinois Food, Drug and Cosmetic Act or Section 406 of this Act
15when medication shopping or pharmacy shopping, or both.
16    (d) When a person has been identified as having 3 or more
17prescribers or 3 or more pharmacies, or both, that do not
18utilize a common electronic file as specified in Section 20 of
19the Pharmacy Practice Act for controlled substances within the
20course of a continuous 30-day period, the Prescription
21Monitoring Program shall may issue an unsolicited report to the
22prescribers, dispensers, and their designees informing them of
23the potential medication shopping. A prescriber who receives
24the report, either personally or through an agent at his or her
25place of practice, shall be prohibited from issuing a
26controlled substance to that same person unless the prescriber

 

 

10000SB1607sam001- 3 -LRB100 11093 RLC 23050 a

1signs a statement on the prescription acknowledging receipt of
2the report. If a pharmacy or pharmacist receives a prescription
3for a person he or she knows or should know to be the subject of
4the report, and the prescriber fails to provide the required
5acknowledgement, the pharmacy or pharmacist must contact the
6prescriber and obtain a signature on the acknowledgement before
7filling the prescription.
8    (e) Nothing in this Section shall be construed to create a
9requirement that any prescriber, dispenser, or pharmacist
10request any patient medication disclosure, report any patient
11activity, or prescribe or refuse to prescribe or dispense any
12medications.
13    (f) This Section shall not be construed to apply to
14inpatients or residents at hospitals or other institutions or
15to institutional pharmacies.
16    (g) Any patient feedback, including grades, ratings, or
17written or verbal statements, in opposition to a clinical
18decision that the prescription of a controlled substance is not
19medically necessary shall not be the basis of any adverse
20action, evaluation, or any other type of negative
21credentialing, contracting, licensure, or employment action
22taken against a prescriber or dispenser.
23(Source: P.A. 99-480, eff. 9-9-15.)
 
24    (720 ILCS 570/316)
25    Sec. 316. Prescription monitoring program.

 

 

10000SB1607sam001- 4 -LRB100 11093 RLC 23050 a

1    (a) The Department must provide for a prescription
2monitoring program for Schedule II, III, IV, and V controlled
3substances that includes the following components and
4requirements:
5        (1) The dispenser must transmit to the central
6    repository, in a form and manner specified by the
7    Department, the following information:
8            (A) The recipient's name and address.
9            (B) The recipient's date of birth and gender.
10            (C) The national drug code number of the controlled
11        substance dispensed.
12            (D) The date the controlled substance is
13        dispensed.
14            (E) The quantity of the controlled substance
15        dispensed and days supply.
16            (F) The dispenser's United States Drug Enforcement
17        Administration registration number.
18            (G) The prescriber's United States Drug
19        Enforcement Administration registration number.
20            (H) The dates the controlled substance
21        prescription is filled.
22            (I) The payment type used to purchase the
23        controlled substance (i.e. Medicaid, cash, third party
24        insurance).
25            (J) The patient location code (i.e. home, nursing
26        home, outpatient, etc.) for the controlled substances

 

 

10000SB1607sam001- 5 -LRB100 11093 RLC 23050 a

1        other than those filled at a retail pharmacy.
2            (K) Any additional information that may be
3        required by the department by administrative rule,
4        including but not limited to information required for
5        compliance with the criteria for electronic reporting
6        of the American Society for Automation and Pharmacy or
7        its successor.
8        (2) The information required to be transmitted under
9    this Section must be transmitted not later than the end of
10    the next business day after the date on which a controlled
11    substance is dispensed, or at such other time as may be
12    required by the Department by administrative rule.
13        (3) A dispenser must transmit the information required
14    under this Section by:
15            (A) an electronic device compatible with the
16        receiving device of the central repository;
17            (B) a computer diskette;
18            (C) a magnetic tape; or
19            (D) a pharmacy universal claim form or Pharmacy
20        Inventory Control form;
21        (4) The Department may impose a civil fine of up to
22    $100 per day for willful failure to report controlled
23    substance dispensing to the Prescription Monitoring
24    Program. The fine shall be calculated on no more than the
25    number of days from the time the report was required to be
26    made until the time the problem was resolved, and shall be

 

 

10000SB1607sam001- 6 -LRB100 11093 RLC 23050 a

1    payable to the Prescription Monitoring Program.
2    (b) The Department, by rule, may include in the monitoring
3program certain other select drugs that are not included in
4Schedule II, III, IV, or V. The prescription monitoring program
5does not apply to controlled substance prescriptions as
6exempted under Section 313.
7    (c) The collection of data on select drugs and scheduled
8substances by the Prescription Monitoring Program may be used
9as a tool for addressing oversight requirements of long-term
10care institutions as set forth by Public Act 96-1372. Long-term
11care pharmacies shall transmit patient medication profiles to
12the Prescription Monitoring Program monthly or more frequently
13as established by administrative rule.
14    (d) The Department of Human Services shall appoint a
15full-time Clinical Director of the Prescription Monitoring
16Program.
17    (e) (Blank). Within one year of the effective date of this
18amendatory Act of the 99th General Assembly, the Department
19shall adopt rules establishing pilot initiatives involving a
20cross-section of hospitals in this State to increase electronic
21integration of a hospital's electronic health record with the
22Prescription Monitoring Program on or before January 1, 2019 to
23ensure all providers have timely access to relevant
24prescription information during the treatment of their
25patients. These rules shall also establish pilots that enhance
26the electronic integration of outpatient pharmacy records with

 

 

10000SB1607sam001- 7 -LRB100 11093 RLC 23050 a

1the Prescription Monitoring Program to allow for faster
2transmission of the information required under this Section. In
3collaboration with the Department of Human Services, the
4Prescription Monitoring Program Advisory Committee shall
5identify funding sources to support the pilot projects in this
6Section and distribution of funds shall be based on voluntary
7and incentive-based models. The rules adopted by the Department
8shall also ensure that the Department continues to monitor
9updates in Electronic Health Record Technology and how other
10states have integrated their prescription monitoring databases
11with Electronic Health Records.
12    (f) Within one year of the effective date of this
13amendatory Act of the 100th General Assembly, the Department
14shall adopt rules requiring all Electronic Health Records
15Systems to interface with the Prescription Monitoring Program
16application program on or before January 1, 2021 to ensure that
17all providers have access to specific patient records during
18the treatment of their patients. These rules shall also address
19the electronic integration of pharmacy records with the
20Prescription Monitoring Program to allow for faster
21transmission of the information required under this Section.
22The Department shall establish actions to be taken if a
23prescriber's Electronic Health Records System does not
24effectively interface with the Prescription Monitoring Program
25within the required timeline.
26    (g) The Department, in consultation with the Advisory

 

 

10000SB1607sam001- 8 -LRB100 11093 RLC 23050 a

1Committee, shall adopt rules allowing licensed prescribers or
2pharmacists who have registered to access the Prescription
3Monitoring Program to authorize a designee to consult the
4Prescription Monitoring Program on their behalf. The rules
5shall include reasonable parameters concerning a
6practitioner's authority to authorize a designee, and the
7eligibility of a person to be selected as a designee.
8(Source: P.A. 99-480, eff. 9-9-15.)".